Gaudium IVF IPO Date, Review, Price and Key Information

Gaudium IVF And Women Health Limited IPO is fully book build issue and it includes both fresh issue and offer for sale. The share offering is a fresh issue of 1.83 crore shares and offer for sale of 0.25 crore shares.

The dates for the Gaudium IVF And Women Health IPO have not been announced yet.

The allotment process is expected to be finalized by [.].

The Gaudium IVF And Women Health IPO is scheduled to list on BSE, NSE, with a tentative listing date of [.].

The price band for the Gaudium IVF And Women Health IPO has not been announced yet.

Registrar for this IPO is Bigshare Services Private Limited and lead managers for Gaudium IVF And Women Health IPO are Sarthi Capital Advisors Private Limited.

IPO Schedule

IPO Open Date	-
IPO Close Date	-
IPO Allotment Date	-
Refund Initiation	-
Share credit in Demat	-
Listing Date	-

Key Details

Price Band	TBA
Lot Size	TBA
Face Value	₹5 Per Equity Share
Total Issue Size	20,886,100 Shares
Fresh Issue	18,354,400 Shares
OFS Issue	2,531,700 Shares
Issue Type	Fresh Issue & Offer for Sale
Listing At	BSE, NSE

Share Reservation

Investor Category	Shares Offered
QIB	50%
Retail	35%
NII/HNI	15%

About Gaudium IVF And Women Health Limited Company

Healthcare Global Enterprises Limited (HCG): Founded in 1998, HCG provides multidisciplinary healthcare services, including oncology, nephrology, neurology, and organ transplants, serving both national and international patients. Key financial indicators show consistent growth. Net sales increased from ₹1,394.78 crore in FY22 to ₹1,907.87 crore in FY24. Operating profit (EBITDA) rose from ₹237.97 crore in FY22 to ₹329.59 crore in FY24. Net profit saw fluctuations, with ₹38.93 crore in FY22, ₹17.63 crore in FY23, and ₹41.33 crore in FY24. Total debt increased to ₹672.76 crore in FY24, while total equity remained relatively stable around ₹865.12 crore.

Kids Clinic India Limited: Established in 2005, Kids Clinic operates 37 centers across 13 Indian cities, specializing in maternity, gynecology, and pediatric care. Financial data is available up to FY23, showing net sales increasing from ₹749.76 crore in FY22 to ₹946.72 crore in FY23. Operating profit (EBITDA) improved from ₹93.49 crore to ₹135.02 crore. However, the company reported net losses of ₹47.16 crore in FY22 and ₹42.57 crore in FY23. Total debt increased to ₹181.85 crore in FY23, while total equity more than doubled to ₹467.39 crore.

Benchmarking and Gaudium IVF: Gaudium IVF and Women Health Limited demonstrates leading profitability margins. In FY24, Gaudium had the highest operating profit margin at 48.01% followed by Healthcare Global at 17.28%. Gaudium also displayed a high PAT margin of 31.86% in FY24. Gaudium’s ROCE for FY24 stood at 65.40% and ROE at 50.24%. Gaudium has a Debt-equity ratio of 0.47x and Interest coverage ratio of 43.62x. However, asset turnover ratios declined due to business expansion and asset growth for both Gaudium and HealthCare Global.

Gaudium IVF Overview: Incorporated in 2015, Gaudium IVF specializes in In Vitro Fertilization (IVF) treatments, operating across India with a hub and spoke model. With over 30 locations, including 7 hubs and 28 spokes, the company also serves international patients. India's IVF market is experiencing substantial growth due to increased infertility rates and awareness, projected to reach USD 1,874 million by CY29. Services include IVF, ICSI, IUI, PCOD/PCOS, and male infertility treatments. Total cycles performed in FY24 numbered 3,711, with 7,208 OPD visits, reflecting the growing demand for fertility treatments.

Gaudium IVF And Women Health Limited Financial Details

Period Ended	30 Sep 2024	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	72.27	57.29	36.63	17.77
Revenue	31.75	3.75	44.26	36.52
Profit After Tax	8.14	16.61	3.52	8.83
Net Worth	41.55	33.27	22.73	9.29
Total Borrowing	19.48	15.73	9.78	5.95

₹ In Crore

Key Performance Indicator

Basic EPS	Return on Net Worth	Net Asset Value	Debt-Equity Ratio	Return on Equity	Return on Capital Employed
2.70	50%	335.98	0.52	49.90%	46.27%

Offer Objectives

The offer includes a Fresh Issue of up to 1,83,54,400 Equity Shares and an Offer for Sale of 25,31,700 Equity Shares by the Promoter Selling Shareholder.

Offer for Sale: The Promoter Selling Shareholder will receive the proceeds, net of expenses and taxes. The Company will not receive any proceeds from the Offer for Sale.

Fresh Issue: The Net Proceeds from the Fresh Issue will be utilized for several key objectives:

Funding Capital Expenditure: Towards establishing new IVF Centers of the Company (₹94.69 crore).
Working Capital: Funding working capital for new IVF Centers (₹3.95 crore).
Investment in EKK Global Private Limited (WOS):
- Launching FMCG products (₹2.92 crore).
- Funding its Working Capital Requirements (₹22.07 crore).
General Corporate Purposes: Amount to be finalized based on the Offer Price.

The funds will be deployed across Fiscal Years 2026 and 2027, based on management estimates and commercial factors. These estimates haven't been appraised by any bank or financial institution, and are subject to revisions due to various factors, including market conditions and regulatory changes.

Any unutilized funds will be carried forward to the next fiscal year. Additional fund requirements will be met through internal accruals and debt/equity arrangements.